Your browser doesn't support javascript.
loading
Prospective cohort study evaluating the association between influenza vaccination and neurodegenerative diseases.
Zhao, Houyu; Zhou, Xuan; Fu, Kexin; Duan, Yunxiao; Wen, Qiaorui; Wang, Shengfeng; Zhan, Siyan.
Afiliação
  • Zhao H; School of Medicine, Chongqing University, Chongqing, China. houyu-zhao@pku.edu.cn.
  • Zhou X; Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China. houyu-zhao@pku.edu.cn.
  • Fu K; Key Laboratory of Epidemiology of Major Diseases (Peking University), Ministry of Education, Beijing, China. houyu-zhao@pku.edu.cn.
  • Duan Y; Department of Biostatistics, School of Global Public Health, New York University, New York, USA.
  • Wen Q; Department of Biostatistics, School of Global Public Health, New York University, New York, USA.
  • Wang S; Department of Biostatistics, Yale School of Public Health, Yale University, New Haven, USA.
  • Zhan S; Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China.
NPJ Vaccines ; 9(1): 51, 2024 Mar 02.
Article em En | MEDLINE | ID: mdl-38431710
ABSTRACT
The effect of influenza vaccination (FluVac) on the risk of neurodegenerative diseases has not been well evaluated in prospective populations. We aimed to assess the association between FluVac and the risk of dementia and Parkinson's disease (PD) in people aged 60 years or older through a prospective population-based cohort from the UK Biobank. A time-varying Cox regression model adjusted for baseline and repeatedly measured covariates was used to estimate the hazard ratio (HR) and 95% confidence interval (CI) of the association between influenza vaccination and risk of dementia/PD. We took into account 70,938 participants in the cohort, including 38,328 participants who got vaccinated. During a median follow-up period of 12.2 years, 2087 incident dementia cases occurred, including 281 cases who received FluVac and 1806 cases who were not vaccinated. In addition, 742 incident PD cases occurred, among whom 131 cases received FluVac and 611 PD cases did not receive FluVac. FluVac was associated with reduced dementia risk with an HR of 0.83 (95% CI, 0.72-0.95) but was not associated with PD incidence (HR = 1.07; 95% CI, 0.87-1.32) after controlling baseline and repeatedly measured covariates. Further, among all dementia cases, there were 733 Alzheimer's disease (AD) (94 vaccinated cases and 639 non-vaccinated cases), 307 vascular dementia (VD) (34 vaccinated cases and 273 non-vaccinated cases), and 1047 cases with other dementias (OD) (153 vaccinated cases and 894 non-vaccinated cases). The HRs for the associations between FluVac and AD, VD, and OD were 0.79 (95% CI, 0.63-1.00), 0.58 (95% CI, 0.39-0.86), and 0.94 (95% CI, 0.78-1.14) respectively. A dose-response relationship was found in the association between FluVac and dementia but not in the association with PD. A major limitation of the study is the low accuracy in the diagnosis of dementia subtypes, namely AD, VD, and OD. However, Results of sensitivity analyses were consistent with the primary analyses. In conclusion, influenza vaccination is significantly associated with a reduced risk of incident dementia but not PD in community-dwelling adults in the UK Biobank population.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article